{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:32:13Z","timestamp":1715596333416},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1007\/s11906-004-0022-8","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T00:32:10Z","timestamp":1179966730000},"page":"279-287","source":"Crossref","is-referenced-by-count":10,"title":["Mineralocorticoid receptor antagonists and hypertension: Is there a rationale?"],"prefix":"10.1007","volume":"6","author":[{"given":"Olga","family":"Gumieniak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon H.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"22_CR1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013719.","journal-title":"N Engl J Med"},{"key":"22_CR2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 2003, 348:1309\u20131321. Large, randomized, placebo-controlled clinical trial of the selective MR antagonist eplerenone added to standard therapy, including ACE-inhibition, in patients with MI complicated by LV dysfunction. The addition of eplerenone resulted in a 15% reduction in all-cause mortality, which confirmed the results of the RALES trial and extended the use of MR antagonists to such patients.","journal-title":"N Engl J Med"},{"key":"22_CR3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1440-1681.2003.03867.x","volume":"30","author":"E Davies","year":"2003","unstructured":"Davies E, MacKenzie SM: Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 2003, 30:437\u2013445.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"22_CR4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","volume":"12","author":"R Rocha","year":"2001","unstructured":"Rocha R, Stier CT Jr: Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001, 12:308\u2013314.","journal-title":"Trends Endocrinol Metab"},{"key":"22_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-7061(96)00301-9","volume":"10","author":"MH Alderman","year":"1997","unstructured":"Alderman MH, Ooi WL, Cohen H, et al.: Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997, 10:1\u20138.","journal-title":"Am J Hypertens"},{"key":"22_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure. Evaluation of Losartan in the Elderly Study (ELITE). Lancet 1997, 349:747\u2013752.","journal-title":"Lancet"},{"key":"22_CR7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"22_CR8","first-page":"821","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821\u2013828.","journal-title":"Lancet"},{"key":"22_CR9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669\u2013677.","journal-title":"N Engl J Med"},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999, 100:1056\u20131064.","journal-title":"Circulation"},{"key":"22_CR11","doi-asserted-by":"crossref","first-page":"17A","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez DA, Bauwens FR, De Buyzere ML, et al.: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993, 71:17A-20A.","journal-title":"Am J Cardiol"},{"key":"22_CR12","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990, 82:1730\u20131736.","journal-title":"Circulation"},{"key":"22_CR13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","volume":"107","author":"JW Conn","year":"1964","unstructured":"Conn JW, Knopf RF, Nesbit RM: Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964, 107:159\u2013172.","journal-title":"Am J Surg"},{"key":"22_CR14","first-page":"401","volume":"45","author":"DG Beevers","year":"1976","unstructured":"Beevers DG, Brown JJ, Ferriss JB, et al.: Renal abnormalities and vascular complications in primary hyperaldosteronism: evidence on tertiary hyperaldosteronism. Q J Med 1976, 45:401\u2013410.","journal-title":"Q J Med"},{"key":"22_CR15","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"22_CR16","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","volume":"143","author":"R Rocha","year":"2002","unstructured":"Rocha R, Martin-Berger CL, Yang P, et al.: Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828\u20134836.","journal-title":"Endocrinology"},{"issue":"2","key":"22_CR17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","volume":"39","author":"DV Martinez","year":"2002","unstructured":"Martinez DV, Rocha R, Matsumura M, et al.: Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002, 39(2 Pt 2):614\u2013618. Study documenting for the first time the critical role of dietary sodium intake in mediating the cardiovascular effects of aldosterone.","journal-title":"Hypertension"},{"key":"22_CR18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597.","journal-title":"Circulation"},{"key":"22_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","volume":"39","author":"J Bauersachs","year":"2002","unstructured":"Bauersachs J, Heck M, Fraccarollo D, et al.: Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002, 39:351\u2013358.","journal-title":"J Am Coll Cardiol"},{"key":"22_CR20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0008-6363(03)00333-X","volume":"58","author":"A Schafer","year":"2003","unstructured":"Schafer A, Fraccarollo D, Hildemann SK, et al.: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003, 58:655\u2013662.","journal-title":"Cardiovasc Res"},{"key":"22_CR21","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","volume":"42","author":"D Fraccarollo","year":"2003","unstructured":"Fraccarollo D, Galuppo P, Hildemann S, et al.: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003, 42:1666\u20131673.","journal-title":"J Am Coll Cardiol"},{"key":"22_CR22","doi-asserted-by":"crossref","unstructured":"Nishiyama A, Yao L, Nagai Y, et al.: Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension 2004, Feb 9 (Epub ahead of print).","DOI":"10.1161\/01.HYP.0000118519.66430.22"},{"key":"22_CR23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000075945","volume":"24","author":"L Hao","year":"2004","unstructured":"Hao L, Kanno Y, Fukushima R, et al.: Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 2004, 24:54\u201360.","journal-title":"Am J Nephrol"},{"key":"22_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.HYP.0000105624.68174.00","volume":"43","author":"RB Paula de","year":"2004","unstructured":"de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41\u201347.","journal-title":"Hypertension"},{"key":"22_CR25","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","volume":"88","author":"JS Williams","year":"2003","unstructured":"Williams JS, Williams GH: 50th Anniversary of aldosterone. J Clin Endocrinol Metab 2003, 88:2364\u20132372.","journal-title":"J Clin Endocrinol Metab"},{"key":"22_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11906-001-0046-2","volume":"3","author":"S Rojagopalan","year":"2001","unstructured":"Rojagopalan S, Pitt B: Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 2001, 3:240\u2013248.","journal-title":"Curr Hypertens Rep"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","volume":"62","author":"R Krattenmacher","year":"2000","unstructured":"Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000, 62:29\u201338.","journal-title":"Contraception"},{"issue":"Suppl3","key":"22_CR28","first-page":"13","volume":"7","author":"IH Thorneycroft","year":"2002","unstructured":"Thorneycroft IH: Yasmin: the reason why. Eur J Contracept Reprod Health Care 2002, 7(Suppl3):13\u201318.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"22_CR29","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ: Eplerenone: cardiovascular protection. Circulation 2003, 107:2512\u20132518.","journal-title":"Circulation"},{"key":"22_CR30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716. Double-blind, placebo-controlled clinical trial of a selective aldosterone receptor antagonist, eplerenone, in hypertensive patients in whom spironolactone was used as a positive control. This study showed that all doses of eplerenone caused a significant reduction in blood pressure compared with placebo. It also demonstrated that the efficacy of eplerenone in blood pressure reduction was approximately 75% that of spironolactone.","journal-title":"Am J Hypertens"},{"key":"22_CR31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Carr AA, Krause S, et al.: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003, 92:38\u201342.","journal-title":"Am J Cardiol"},{"key":"22_CR32","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","volume":"25","author":"ED Burgess","year":"2003","unstructured":"Burgess ED, Lacourciere Y, Ruilope-Urioste LM, et al.: Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003, 25:2388\u20132404. This open-label, uncontrolled trial of up to 14 months duration provided important information on the long-term safety and efficacy of eplerenone in patients with essential hypertension.","journal-title":"Clin Ther"},{"key":"22_CR33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155. Black patients have a higher prevalence of volume-dependent hypertension and blood pressure salt-sensitivity. This double-blind, placebo-controlled trial demonstrated that eplerenone was equally effective in white and black subjects, suggesting that the volumemodifying effect of MR blockade is not the only mechanism involved in MR blockade\u2019s role in reducing blood pressure.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl5","key":"22_CR34","first-page":"3","volume":"17","author":"HR Black","year":"1999","unstructured":"Black HR, Kuller LH, O\u2019Rourke MF, et al.: The first report of the Systolic and Pulse Pressure (SYPP) Working Group. J Hypertens 1999, 17(Suppl5):3\u201314.","journal-title":"J Hypertens"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021\u20131026. Clinical trial that demonstrated the similar efficacy of MR blockade with eplerenone to calcium-channel blockade with amlodipine in older patients with isolated systolic hypertension and widened pulse pressure.","journal-title":"Hypertension"},{"key":"22_CR36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123.","journal-title":"Hypertension"},{"key":"22_CR37","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831\u20131838. This randomized, double-blind trial showed that eplerenone was as effective as enalapril in regressing LVH. The combination therapy resulted in a significantly greater benefit than eplerenone alone, suggesting that the cardiovascular benefit of eplerenone is additive with an ACE-inhibition.","journal-title":"Circulation"},{"key":"22_CR38","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002, 15:24A. This clinical trial showed that hypertensive patients with type 2 diabetes mellitus had similar reductions in microalbuminuria with eplerenone and enalapril treatments. However, the combination produced a greater reduction in proteinuria than either therapy alone, which suggests that blocking effects of angiotensin II and aldosterone may confer a greater renal protection.","journal-title":"Am J Hypertens"},{"key":"22_CR39","first-page":"F","volume":"14","author":"M Epstein","year":"2003","unstructured":"Epstein M, Wienberger M, Lewin A, et al.: The selective aldosterone blocker eplerenone reduces proteinuria without concominant hyperkalemia. J Amer Soc Nephrol 2003, 14(Abstracts Issue):F-FC026, 6A. The results of this trial suggest that the cardiovascular benefits of MR blockade might be achieved with a lower dose of eplerenone, which is associated with lower incidence of hyperkalemia.","journal-title":"J Amer Soc Nephrol"},{"issue":"13","key":"22_CR40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","volume":"163","author":"NK Hollenberg","year":"2003","unstructured":"Hollenberg NK, Williams GH, Anderson R, et al.: Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003, 163(13):1543\u20131548.","journal-title":"Arch Intern Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0022-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-004-0022-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0022-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:08Z","timestamp":1559434568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-004-0022-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s11906-004-0022-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}